| | | |

Evaluating Mesothelioma Symptoms: New Tool Makes it Easier

ByAlex Strauss
evaluating mesothelioma symptoms

Evaluating mesothelioma symptoms is an important step in planning treatment for asbestos cancer. But researchers at a top US cancer center say it is hard to do a thorough job using current tools.

That’s why doctors at MD Anderson have developed their own method for evaluating mesothelioma symptoms. They made some mesothelioma-specific additions to an existing cancer symptom evaluation system.

Tests on more than 200 mesothelioma patients show the method works well and is easy to use. The developers hope doctors can use it to design better mesothelioma treatment plans.

The Importance of Evaluating Mesothelioma Symptoms

When a patient receives a mesothelioma diagnosis, the next step is evaluating mesothelioma symptoms. This process can help give the doctor valuable information about how the body is coping with the cancer and the treatment.

A questionnaire is a simple and objective way of evaluating mesothelioma symptoms. Patients may complete a symptom assessment questionnaire several times throughout their treatment. Tracking symptoms over time can show doctors what is working and what may need to be changed.

In Search of a Better Assessment Tool

The MD Anderson Symptom Inventory (MDASI) was developed for clinicians and researchers. It asks patients to rate the severity of 13 common symptoms of cancer – such as pain and fatigue – and six ways they may be interfering with a patient’s daily life. The inventory asks about things like walking, activity, and relationships. Each item gets a score between 0 and 10.

MDASI was not specifically designed for evaluating mesothelioma symptoms. Mesothelioma patients have many of the same symptoms and problems as other cancer patients. But they also have certain issues that are unique to mesothelioma.

The MD Anderson team used what they know about these differences to create a mesothelioma-specific version of MDASI. In a recent study, 248 mesothelioma patients answered the MDASI-MPM questionnaire several times during mesothelioma therapy.

The researchers say MDASI-MPM makes evaluating mesothelioma symptoms easier and more effective. In an article in the Journal of Patient Reported Outcomes, they call it “valid, reliable, and responsive”.

Knowing the Signs of Mesothelioma

Anyone with a history of asbestos exposure should understand the importance of evaluating mesothelioma symptoms. Asbestos is the number one cause of mesothelioma.

There is no known way of preventing mesothelioma after exposure. But mesothelioma patients who receive treatment in the early stages of the disease typically have the best outcomes.

Early warning signs of pleural mesothelioma include shortness of breath, persistent cough, and chest pain. People with peritoneal mesothelioma often complain of bloating, abdominal pain, and digestive issues.

Source:

Mendoza, TR, et al, “Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)”, June 17, 2019, Journal of Patient Reported Outcomes, https://jpro.springeropen.com/articles/10.1186/s41687-019-0122-5

The MD Anderson Symptom Inventory, MD Anderson Cancer Center website, https://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/symptom-research/symptom-assessment-tools/md-anderson-symptom-inventory.html

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…